Thirty-foar cases of duodenal ulcer with Hp osity weve treated with Ompeperazole, Amoxi-cillin and Tindazole, which were compared with 34 cases of Hp positive duodenal ulcer treated with omeperazole only. The duration...Thirty-foar cases of duodenal ulcer with Hp osity weve treated with Ompeperazole, Amoxi-cillin and Tindazole, which were compared with 34 cases of Hp positive duodenal ulcer treated with omeperazole only. The duration of treatment were both one week and all the patients were re-examed at one month after treatment. The result showed that the huring rate of ulcers (HRU) in triple therapy group was 88. 2%, uhile that of the contr group was 82. 3%. No significant difference was observed in the two groups (p>0.05). Hp eradication rate (HER) in triple therapy group was 91. 7%, while that of the control group was 41. 1 %. There was significant difference between the HERs of the two gronps (p<0.01 ). In the 45 cases with Hp eradication, ulcers in 44 cases hared, with huring rate of 97. 8%. In the 23cases without Hp eradication, ulcers in 14 cases hured, with huring rate of 60. 9%. There was significant difference between these two gronps (p<0.05), which suggested the significant improvement of HRU of-ter Hp eradication. The triple therapy has the advantages such as high HRU, high rate of tolerance and no severe side effects. The therapy deserve recomrnendation clinically.展开更多
Background Although previous clinical study revealed that bortezomib combined with dexamethasone had improved the outcomes of relapsed or refractory multiple myeloma （RRMM）, the optimal dose combinations of bortezom...Background Although previous clinical study revealed that bortezomib combined with dexamethasone had improved the outcomes of relapsed or refractory multiple myeloma （RRMM）, the optimal dose combinations of bortezomib and dexamethasone remain unknown. This trial aimed to observe the efficacy and safety of different dose combinations of bortezomib and dexamethasone in the treatment of RRMM patients in China.Methods A total of 168 patients with relapsed multiple myeloma （MM） who were refractory to at lest two prior treatments were enrolled in this multicenter, open-label, non-randomized, prospective clinical trial. Twenty patients received 1.3 mg/m2 of bortezomib twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles and oral or intravenous dexamethasone 20 mg on the day of and after each bortezomib dose （group 1）; 66 patients received less than 1.3 mg/m2（0.7-1.0 mg/m2） of bortezomib and dexamethasone 20 mg on the same schedule （group 2）; 37 patients received 1.3 mg/m2 of bortezomib and dexamethasone 40 mg （group 3） and 45 patients received less than 1.3 mg/m2 （0.7-1.0 mg/m2）of bortezomib and dexamethasone 40 mg （group 4）. The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0. Results The median age of groups 1 to 4 was 61,62, 56, and 60 years, respectively. Most patients were in stages Ⅱ/Ⅲ of MM and the most common subtype was IgG The rate of overall response to bortezomib and dexamethasone of group 1 to 4 was 72.2% （13/18）, 73.8% （48/65）, 78.8% （26/33） and 78.0% （32/41） （P=0.91）, including a complete response rate of 22.2% （4/18）, 20.0% （13/65）, 33.3% （11/33） and 29.3% （12/41） （P=0.67）, respectively. There was no statistical significance in time to progression and overall survival among these 4 groups （P 〉0.05）. The most commonly adverse events of any grade in the entire 4 groups were fatigue, gastrointestinal effects, peripheral neuropathy and thrombocytopenia, and there was no significance in the number of adverse events among the 4 groups （P 〉0.05） except that peripheral neuropathy was reported more frequently in group 3 （36.3%） than in group 2 （13.8%, P 〈0.05） and group 4 （14.6%, P〈O.05）.Conclusions The combination of bortezomib and dexamethasone was associated with high responses in Chinese RRMM patients. No significant differences of efficacy were detected in different dose combinations of bortezomib and dexamethasone. Moreover, low dose of bortezomib reduced the incidence of peripheral neuropathy without affecting outcome in the treatment of patients with RRMM in China.展开更多
Background Great advances have been made in the diagnosis, molecular pathogenesis and treatment of acute lymphoblastic leukemia （ALL） in the past decade. Due to the lack of large population-based studies, the recent...Background Great advances have been made in the diagnosis, molecular pathogenesis and treatment of acute lymphoblastic leukemia （ALL） in the past decade. Due to the lack of large population-based studies, the recent trends in the incidence and geographic variations of ALL in Shanghai, China have not been well documented. To better understand the incidence and epidemiological features of ALL in Shanghai, we conducted a retrospective survey based on the database from the Shanghai Center for Disease Control and Prevention （CDC） and the medical records in all large-scale hospitals in Shanghai, especially those 30 major hospitals with hematology department. Methods According to the data from Shanghai CDC, 544 patients, with a median age of 32 years （ranging 1.2-89 years）, were diagnosed as de novo ALL from January 1, 2002 to December 31, 2006, and they were followed up until December 31,2007. Results The average annual incidence of ALL in Shanghai was 0.81/100 000. The incidence in men （0.86/100 000） was slightly higher than that in women （0.75/100 000）. The age-stratified incidence showed that the incidence was 2.31/100 000 in patients 〈17 years old, 0.54/100 000 in those 18-34 years old, 0.46/100 000 in those 35-59 years old, and 0.94/100 000 in those 〉60 years old. Moreover, there were substantial geographic variations in the incidence of ALL, with the incidence in Chongming county, an island in the east of Shanghai city being 0.60/100 000, much lower than those of other districts. Both French-American-British （FAB） and World Health Organization （WHO） classification systems were applied in the present study. Eighty-eight patients were diagnosed as L1 （26.2%）, 193 L2 （57.4%）, and 55 L3 （16.4%）. For 302 patients with immunophenotypic results, 242 were identified as B cell origin （80.1%）, 59 as T cell origin （19.5%）, and 1 as biphenotype （0.4%）. The leukemia cells in 61 patients co-expressed one or two myeloid antigen （20.2%）. For 269 patients with cytogenetic results, the incidences of t（9;22） in patients aged 〈10, 11-17, 18-44, 45-59 and 〉60 years old were 4.2%, 11.4%, 19.2%, 23.1% and 5.3%, respectively. Conclusion Compared with the previous data, the incidence of ALL is increased in Shanghai, and has a geographic distribution characteristic.展开更多
文摘Thirty-foar cases of duodenal ulcer with Hp osity weve treated with Ompeperazole, Amoxi-cillin and Tindazole, which were compared with 34 cases of Hp positive duodenal ulcer treated with omeperazole only. The duration of treatment were both one week and all the patients were re-examed at one month after treatment. The result showed that the huring rate of ulcers (HRU) in triple therapy group was 88. 2%, uhile that of the contr group was 82. 3%. No significant difference was observed in the two groups (p>0.05). Hp eradication rate (HER) in triple therapy group was 91. 7%, while that of the control group was 41. 1 %. There was significant difference between the HERs of the two gronps (p<0.01 ). In the 45 cases with Hp eradication, ulcers in 44 cases hared, with huring rate of 97. 8%. In the 23cases without Hp eradication, ulcers in 14 cases hured, with huring rate of 60. 9%. There was significant difference between these two gronps (p<0.05), which suggested the significant improvement of HRU of-ter Hp eradication. The triple therapy has the advantages such as high HRU, high rate of tolerance and no severe side effects. The therapy deserve recomrnendation clinically.
文摘Background Although previous clinical study revealed that bortezomib combined with dexamethasone had improved the outcomes of relapsed or refractory multiple myeloma （RRMM）, the optimal dose combinations of bortezomib and dexamethasone remain unknown. This trial aimed to observe the efficacy and safety of different dose combinations of bortezomib and dexamethasone in the treatment of RRMM patients in China.Methods A total of 168 patients with relapsed multiple myeloma （MM） who were refractory to at lest two prior treatments were enrolled in this multicenter, open-label, non-randomized, prospective clinical trial. Twenty patients received 1.3 mg/m2 of bortezomib twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles and oral or intravenous dexamethasone 20 mg on the day of and after each bortezomib dose （group 1）; 66 patients received less than 1.3 mg/m2（0.7-1.0 mg/m2） of bortezomib and dexamethasone 20 mg on the same schedule （group 2）; 37 patients received 1.3 mg/m2 of bortezomib and dexamethasone 40 mg （group 3） and 45 patients received less than 1.3 mg/m2 （0.7-1.0 mg/m2）of bortezomib and dexamethasone 40 mg （group 4）. The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0. Results The median age of groups 1 to 4 was 61,62, 56, and 60 years, respectively. Most patients were in stages Ⅱ/Ⅲ of MM and the most common subtype was IgG The rate of overall response to bortezomib and dexamethasone of group 1 to 4 was 72.2% （13/18）, 73.8% （48/65）, 78.8% （26/33） and 78.0% （32/41） （P=0.91）, including a complete response rate of 22.2% （4/18）, 20.0% （13/65）, 33.3% （11/33） and 29.3% （12/41） （P=0.67）, respectively. There was no statistical significance in time to progression and overall survival among these 4 groups （P 〉0.05）. The most commonly adverse events of any grade in the entire 4 groups were fatigue, gastrointestinal effects, peripheral neuropathy and thrombocytopenia, and there was no significance in the number of adverse events among the 4 groups （P 〉0.05） except that peripheral neuropathy was reported more frequently in group 3 （36.3%） than in group 2 （13.8%, P 〈0.05） and group 4 （14.6%, P〈O.05）.Conclusions The combination of bortezomib and dexamethasone was associated with high responses in Chinese RRMM patients. No significant differences of efficacy were detected in different dose combinations of bortezomib and dexamethasone. Moreover, low dose of bortezomib reduced the incidence of peripheral neuropathy without affecting outcome in the treatment of patients with RRMM in China.
文摘Background Great advances have been made in the diagnosis, molecular pathogenesis and treatment of acute lymphoblastic leukemia （ALL） in the past decade. Due to the lack of large population-based studies, the recent trends in the incidence and geographic variations of ALL in Shanghai, China have not been well documented. To better understand the incidence and epidemiological features of ALL in Shanghai, we conducted a retrospective survey based on the database from the Shanghai Center for Disease Control and Prevention （CDC） and the medical records in all large-scale hospitals in Shanghai, especially those 30 major hospitals with hematology department. Methods According to the data from Shanghai CDC, 544 patients, with a median age of 32 years （ranging 1.2-89 years）, were diagnosed as de novo ALL from January 1, 2002 to December 31, 2006, and they were followed up until December 31,2007. Results The average annual incidence of ALL in Shanghai was 0.81/100 000. The incidence in men （0.86/100 000） was slightly higher than that in women （0.75/100 000）. The age-stratified incidence showed that the incidence was 2.31/100 000 in patients 〈17 years old, 0.54/100 000 in those 18-34 years old, 0.46/100 000 in those 35-59 years old, and 0.94/100 000 in those 〉60 years old. Moreover, there were substantial geographic variations in the incidence of ALL, with the incidence in Chongming county, an island in the east of Shanghai city being 0.60/100 000, much lower than those of other districts. Both French-American-British （FAB） and World Health Organization （WHO） classification systems were applied in the present study. Eighty-eight patients were diagnosed as L1 （26.2%）, 193 L2 （57.4%）, and 55 L3 （16.4%）. For 302 patients with immunophenotypic results, 242 were identified as B cell origin （80.1%）, 59 as T cell origin （19.5%）, and 1 as biphenotype （0.4%）. The leukemia cells in 61 patients co-expressed one or two myeloid antigen （20.2%）. For 269 patients with cytogenetic results, the incidences of t（9;22） in patients aged 〈10, 11-17, 18-44, 45-59 and 〉60 years old were 4.2%, 11.4%, 19.2%, 23.1% and 5.3%, respectively. Conclusion Compared with the previous data, the incidence of ALL is increased in Shanghai, and has a geographic distribution characteristic.
